YTHDF2 and squamous cell carcinoma: In the squamous cell carcinoma group not receiving PD-1/PD-L1 inhibitor treatment, the immunohistochemical expression of YTHDF1 or YTHDF2 showed a trend toward better overall survival but was not statistically significant (p = 0.062, Figure 4B and p = 0.097, Figure 4D, respectively).